Luminex (LMNX) Return on Equity ROE from the first quarter 2021 to first quarter 2020 and annually, average high and low, overall ranking from Mar 31 2021 to Mar 31 2020 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Luminex Corporation  (NASDAQ: LMNX)

Luminex's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Luminex in the first quarter 2021?
Luminex Corporation achieved a return on average equity (ROE) of 16.15 % in its first quarter 2021, this is above LMNX's average return on equity of 0%.
Luminex Corporation shareholder's equity over the 12 months ending in its first quarter 2021 are valued at $385 million

ROE has advanced compared to 8.76% in the fourth quarter 2020, due to net income growth.

Within the Medical Equipment & Supplies industry Luminex Corporation achieved the highest return on equity. While the total ranking for ROE unchanged, relative to the fourth quarter 2020 at no. .

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2021)
I. Quarter		 (Dec 31 2020)
IV. Quarter		 (Sep 30 2020)
III. Quarter		 (Jun 30 2020)
II. Quarter		 (Mar 31 2020)
I. Quarter
Y / Y Equity Change - 11.37 % 12.22 % 8.21 % -
Y / Y Net Income Change 1100 % 61.84 % 1572.78 % 2687.13 % -74.14 %
Net Income (TTM) in Millions 62 44 42 34 7
Return On Equity (TTM) 16.15 % 8.76 % 8.57 % 7.17 % 1.42 %
LMNX's Total Ranking # # # # #
Equity (TTM) in Millions 0 518 516 504 463
Seq. Equity Change - 0.31 % 2.35 % 9.03 % -0.51 %
Seq. Net Income Change 264.27 % -34.01 % -70.76 % 1607.16 % -50.87 %

Back to LMNX Management Effectiveness >> LMNX's 5 Years Annual ROE >> Compare LMNX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





LMNX Annual Return On Equity (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016
Total Equity in Millions 518 465 468 438 404
Y / Y Equity Change 11.37 % -0.6 % 6.79 % 8.48 % 9.54 %
Net Income in Millions 44 6 19 29 14
Y / Y Net Income Change 664.76 % -69.05 % -35.95 % 109.16 % -62.52 %
Return On Equity 8.46 % 1.23 % 3.96 % 6.6 % 3.42 %

Back to LMNX Management Effectiveness >> LMNX's 5 Years Annual ROE >> Compare LMNX ROE to its Competitors




Annual Roe Comment
In 2020 ROE improved to 8.46 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LMNX's' Return on Equity at Yahoo Finance
LMNX's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LMNX's Competitors
Subscribers only: Roe for Luminex's Suppliers
Subscribers only: Return On Equity for LMNX's Customers




Companies with similar Return On Equity at Mar 31 2021, within Healthcare Sector ROE
Kronos Bio Inc   43.51 %
Harrow Inc   40.92 %
Neurocrine Biosciences Inc   40.53 %
Chemed Corporation  38.91 %
Progyny Inc   38.86 %
Pro dex Inc   38.65 %
Elite Pharmaceuticals Inc   38.25 %
Regeneron Pharmaceuticals Inc   37.96 %
Viemed Healthcare Inc   37.21 %
Abbvie Inc   36.35 %
Dexcom Inc   35.06 %
Lifevantage Corp  34.67 %
Vertex Pharmaceuticals Inc  33.16 %
Select Medical Holdings Corp  32.94 %
Meridian Bioscience Inc   32.57 %
Revvity Inc  30.81 %
Labcorp Holdings Inc   30.24 %
Voyager Therapeutics Inc   29.50 %
Oramed Pharmaceuticals Inc  29.17 %
Quest Diagnostics Inc  29.05 %
Emergent Biosolutions Inc   28.41 %
Vaso Corporation  28.36 %
Biogen Inc   28.33 %
Blueprint Medicines Corporation  27.26 %
Lakeland Industries Inc   26.89 %
Amedisys Inc  26.42 %
Pacira Biosciences inc   26.34 %
Biodelivery Sciences International Inc   26.13 %
Merck and Co Inc   25.76 %
Collegium Pharmaceutical Inc   24.52 %

Date modified: 2026-09-26T07:16:16+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.